[1]张 诚,丁建玲,麦麦提依明·托合提,等.P53、EGFR在胶质瘤组织中的表达及意义[J].医学信息,2020,33(07):94-96.[doi:10.3969/j.issn.1006-1959.2020.07.026]
　ZHANG Cheng,DING Jian-ling,McMatti Yiming Tohetti,et al.Expression and Significance of P53 and EGFR in Glioma Tissues[J].Medical Information,2020,33(07):94-96.[doi:10.3969/j.issn.1006-1959.2020.07.026]
点击复制

P53、EGFR在胶质瘤组织中的表达及意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年07期
页码:
94-96
栏目:
论著
出版日期:
2020-04-01

文章信息/Info

Title:
Expression and Significance of P53 and EGFR in Glioma Tissues
文章编号:
1006-1959（2020）07-0094-03
作者:
张 诚; 丁建玲; 麦麦提依明·托合提; 等
（新疆维吾尔自治区人民医院神经外科1，心外科2，新疆 乌鲁木齐 830000）
Author(s):
ZHANG Cheng; DING Jian-ling; McMatti Yiming Tohetti; et al
(Department of Neurosurgery1,Department of Cardiac Surgery2,People’s Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830000,Xinjiang,China)
关键词:
胶质瘤; P53; EGFR
Keywords:
Glioma; P53; EGFR
分类号:
R739.41
DOI:
10.3969/j.issn.1006-1959.2020.07.026
文献标志码:
A
摘要:
目的 评估P53、表皮样生长因子受体（EGFR）在胶质细胞瘤患者组织中的表达情况，分析二者与胶质瘤分级的相关性。方法 选取2018年1月~2019年7月新疆维吾尔自治区人民医院确诊胶质瘤患者组织标本40例作为实验组，选取同期脑外伤或高血压脑出血患者手术切除的正常脑组织15例为对照组，采用S-P免疫组化法检测实验组及对照组标本中的P53及EGFR在胶质瘤中的表达情况，分析P53及EGFR与胶质瘤分级的相关性。结果 实验组不同性别、年龄及肿瘤大小中P53、EGFR的表达比较，差异无统计学意义（P＞0.05）；实验组脑组织中P53及EGFR阳性表达率均高于对照组，差异有统计学意义（P＜0.05）；P53、EGFR在不同级别胶质瘤中阳性表达率均呈正相关（r=0.057、0.520，P=0.012、0.017）。脑胶质瘤组织中P53与EGFR表达无明显相关性（r=0.436，P=0.052）。结论 脑胶质瘤组织中P53、EGFR的表达可能与性别、年龄及肿瘤大小无关，P53、EGFR在不同级别胶质瘤中阳性表达率均较高，且胶质瘤级别越高，组织P53、EGFR阳性率越高，联合检测P53及EGFR可能作为胶质瘤分子病理诊断的新指标。
Abstract:
Objective To evaluate the expression of P53 and epidermoid growth factor receptor (EGFR) in the tissues of patients with glioma, and to analyze the correlation between the two and the grade of glioma.Methods From January 2018 to July 2019, 40 patients with glioma diagnosed in Xinjiang Uygur Autonomous Region were selected as the experimental group, and 15 normal brain tissues surgically removed from patients with brain trauma or hypertensive cerebral hemorrhage during the same period were selected as the control group. S-P immunohistochemical method was used to detect the expression of P53 and EGFR in gliomas in the experimental and control samples, and to analyze the correlation between P53 and EGFR and the grade of glioma.Results There was no statistically significant difference in the expression of P53 and EGFR in different genders, ages and tumor sizes in the experimental group (P>0.05); the positive expression rates of P53 and EGFR in the brain tissue of the experimental group were higher than that of the control group,the difference was statistically significant (P<0.05); The positive expression rates of P53 and EGFR in different grades of gliomas were positively correlated (r=0.057, 0.520, P=0.012, 0.017). There was no significant correlation between P53 and EGFR expression in glioma tissues (r=0.436, P=0.052).Conclusion The expression of P53 and EGFR in glioma tissue may not be related to gender, age and tumor size. The positive expression rates of P53 and EGFR in gliomas of different grades are higher, and the higher the grade of glioma, the tissue P53 and EGFR The higher the positive rate, the joint detection of P53 and EGFR may be used as a new indicator of molecular pathological diagnosis of glioma.

参考文献/References:

[1]Khasraw M,Ameratunga MS,Grant R,et al.Antiangiogenic therapy for high-grade glioma[J].Cochrane Database Syst Rev,2014,9(9):CD008218.[2]赵清爽,王守森.TP53在髓母细胞瘤分子分型中的临床意义与相关研究进展[J].临床神经外科杂志,2017,14(4):315-318.[3]Canale M,Petracci E,Delmonte A,et al.Impact of TP53 mutations on outcome in EGFR-mutated patients treated with firstline tyrosine kinase inhibitors[J].Clin Cancer Res,2017,23(9):2195-2202.[4]Meder L,Konig L,Ozretic L,et al.NOTCH，ASCL1,p53 and RB alterations define an alternative patway driving neuroendocrine and small cell lung carcinomas[J].Int J Cancer,2016,138(4):927-938.[5]Rao S,Kanuri NN,Nimbalkar V,et al.High frequency of H3K27M immunopositivity in adult thalamic glioblastoma[J].Neuropathology,2019,39(2):78-84.[6]McNulty SN,Cottrell CE,Vigh-Conrad KA,et al.Beyond sequence variation:assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling[J].Human Pathology,2019(86):170-181.[7]Ogura R,Tsukamoto Y,Natsumeda M,et al.Immunohistochemical profiles of IDH1,MGMT and P53:Practical significance for prognostication of patients with diffuse gliomas[J].Neuropathology,2015,35(4):324-335.[8]Le Rhun E,Preusser M,Roth Pl.et al.Molecular targeted therapy of glioblastoma[J].Cancer Treatment Review,2019(80):1-13.[9]刘坤,王海江,孙振强,等.胃癌组织HER-2和VEGF及EGFR表达临床意义研究[J].中华肿瘤防治杂志,2015,22(10):781-785.[10]殷长江,董保忠,杜晓光,等.脑胶质瘤患者围术期脑脊液中HGF、TNF-α、IL-17水平变化及意义[J].山东医药,2016,56(9):51-52.

相似文献/References:

[1]张小龙.P53在胆囊癌临床预后中的预测意义[J].医学信息,2018,31(11):156.[doi:10.3969/j.issn.1006-1959.2018.11.051]
　ZHANG Xiao-long.Predictive Significance of P53 in Clinical Prognosis of Gallbladder Carcinoma[J].Medical Information,2018,31(07):156.[doi:10.3969/j.issn.1006-1959.2018.11.051]
[2]吴 刚,袁华兵.阿瑞匹坦对于改善Ⅲ~Ⅳ期颅内胶质瘤患者CINV的研究[J].医学信息,2019,32(13):87.[doi:10.3969/j.issn.1006-1959.2019.13.024]
　WU Gang,YUAN Hua-bing.Study on the Effect of Aprepitant on Improving CINV in Patients with Stage III~IV Intracranial Glioma[J].Medical Information,2019,32(07):87.[doi:10.3969/j.issn.1006-1959.2019.13.024]
[3]王 露,陈思敏,赵苏苏,等.子宫内膜样子宫内膜癌中错配修复基因表达与临床病理及相关基因表达的关系[J].医学信息,2020,33(14):61.[doi:10.3969/j.issn.1006-1959.2020.14.019]
　WANG Lu,CHEN Si-min,ZHAO Su-su,et al.Relationship Between Mismatch Repair Gene Expression and Clinicopathology and Related Gene Expression in Endometrioid Endometrial Carcinoma[J].Medical Information,2020,33(07):61.[doi:10.3969/j.issn.1006-1959.2020.14.019]
[4]程 哲,汪潮潮,吴 娟,等.BFAR在胶质瘤中的表达及其与胶质瘤预后的关系[J].医学信息,2021,34(07):78.[doi:10.3969/j.issn.1006-1959.2021.07.021]
　CHENG Zhe,WANG Chao-chao,WU Juan,et al.The Expression of BFAR in Glioma and Its Relationship with the Prognosis of Glioma[J].Medical Information,2021,34(07):78.[doi:10.3969/j.issn.1006-1959.2021.07.021]
[5]尹 江,张志杰,贺智敏.miRNA205在神经胶质瘤细胞放疗敏感性中的作用[J].医学信息,2021,34(13):1.[doi:10.3969/j.issn.1006-1959.2021.13.001]
　YIN Jiang,ZHANG Zhi-jie,HE Zhi-min.The Role of miRNA205 in the Sensitivity of Glioma Cells to Radiotherapy[J].Medical Information,2021,34(07):1.[doi:10.3969/j.issn.1006-1959.2021.13.001]
[6]刘钰婵,张 威,邱 俊,等.感兴趣区选取数量对脑胶质瘤IVIM参数测量的影响[J].医学信息,2022,35(01):84.[doi:10.3969/j.issn.1006-1959.2022.01.020]
　LIU Yu-chan,ZHANG Wei,QIU Jun,et al.The Influence of the Number of Selected ROIs on the Measurement of IVIM Parameters of Glioma[J].Medical Information,2022,35(07):84.[doi:10.3969/j.issn.1006-1959.2022.01.020]
[7]张 群,田秋思,唐铖铖,等.基于生物信息学检测NSUN2基因在胶质瘤中的表达及临床意义[J].医学信息,2022,35(04):1.[doi:10.3969/j.issn.1006-1959.2022.04.001]
　ZHANG Qun,TIAN Qiu-si,TANG Cheng-cheng,et al.Detection of NSUN2 Gene Expression in Glioma Based on Bioinformatics and its Clinical Significance[J].Medical Information,2022,35(07):1.[doi:10.3969/j.issn.1006-1959.2022.04.001]
[8]谢 炯,戚 继.PEX基因转染人脐带间充质干细胞的体外培养及鉴定[J].医学信息,2023,36(10):88.[doi:10.3969/j.issn.1006-1959.2023.10.020]
　XIE Jiong,QI Ji.In Vitro Culture and Identificationg of Human Umbilical Cord Mesenchymal Stem Cells Modified by PEX Gene[J].Medical Information,2023,36(07):88.[doi:10.3969/j.issn.1006-1959.2023.10.020]
[9]胡彩虹,王志浩,方思琪,等.CARM1在胶质瘤发生发展中的作用研究[J].医学信息,2022,35(06):77.[doi:10.3969/j.issn.1006-1959.2022.06.019]
　HU Cai-hong,WANG Zhi-hao,FANG Si-qi,et al.The Role of CARM1 in the Development of Glioma[J].Medical Information,2022,35(07):77.[doi:10.3969/j.issn.1006-1959.2022.06.019]

更新日期/Last Update: 2020-04-01